Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Respiratory syncytial virus prevention in children with congenital heart disease: who and how?

  • Kim, Nam-Kyun (Division of Pediatric Cardiology, Department of Pediatrics, Severance Cardiovascular Hospital, Yonsei University Health System) ;
  • Choi, Jae-Young (Division of Pediatric Cardiology, Department of Pediatrics, Severance Cardiovascular Hospital, Yonsei University Health System)
  • 투고 : 2011.03.28
  • 심사 : 2011.04.25
  • 발행 : 2011.05.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Respiratory syncytial virus (RSV) is a major cause of respiratory infection in children. Most of the pediatric population have RSV infection before the age of 2, and recurrent infections are common even within one season. Chronic lung disease, prematurity, along with congenital heart disease (CHD) are major risk factors in severe lower respiratory infection. In hemo-dynamically significant CHD patients with RSV infection, hospitalization is usually needed and the possibility of treatment in intensive care unit and the use of mechanical ventilator support are known to increase. Therefore the prevention of RSV infection in CHD patients is mandatory. The current standard for RSV prevention is immunoprophylaxis by palivizumab. Immunoprophylaxis is recommended monthly in hemodynamically significant CHD patients, up to 5 months. Motabizumab, a second generation drug and newly developing RSV vaccines are also expected to play a key role in RSV prevention in the future. The prophylaxis of RSV infection in CHD patients is cost-effective in both the medical aspect of the patients as well as the socio-economic aspect. Therefore an effort to promote prevention should be made by not only the family of the patients but also by the government.

키워드

참고문헌

  1. Groothuis JR, Hoopes JM, Jessie VG. Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention. Adv Ther 2011;28:91-109. https://doi.org/10.1007/s12325-010-0100-z
  2. Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements-Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009;124:1694-701. https://doi.org/10.1542/peds.2009-2345
  3. Welliver RC Sr, Checchia PA, Bauman JH, Fernandes AW, Mahadevia PJ, Hall CB. Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Curr Med Res Opin 2010;26:2175-81. https://doi.org/10.1185/03007995.2010.505126
  4. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-40. https://doi.org/10.1067/S0022-3476(03)00454-2
  5. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997;176:1215-24. https://doi.org/10.1086/514115
  6. Tulloh R, Marsh M, Blackburn M, Casey F, Lenney W, Weller P, et al. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young 2003;13:420-3.
  7. Kristensen K, Stensballe LG, Bjerre J, Roth D, Fisker N, Kongstad T, et al. Risk factors for respiratory syncytial virus hospitalisation in children with heart disease. Arch Dis Child 2009;94:785-9. https://doi.org/10.1136/adc.2008.143057
  8. Subcommittee on diagnosis and management of bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics 2006;118:1774-93. https://doi.org/10.1542/peds.2006-2223
  9. Kneyber Mcj EW, Steyerberg R, de Groot HA, Moll HA. Long-term effects of respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a quantitative review. Acta Paediatr 2000;89:654-60. https://doi.org/10.1111/j.1651-2227.2000.tb00359.x
  10. Hall CB, Douglas RG Jr. Nosocomial respiratory syncytial viral infections. Should gowns and masks be used? Am J Dis Child 1981;135:512-5. https://doi.org/10.1001/archpedi.1981.02130300012006
  11. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997;99:93-9. https://doi.org/10.1542/peds.99.1.93
  12. Simoes EA, Sondheimer HM, Top FH, Meissner HC, Welliver RC, Kramer AA, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr 1998;133:492-9. https://doi.org/10.1016/S0022-3476(98)70056-3
  13. Samson L. Prevention of respiratory syncytial virus infection. Paediatr Child Health 2009;14:521-32. https://doi.org/10.1093/pch/14.8.521
  14. Groothuis JR, Hoopes JM, Hemming VG. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis. Adv Ther 2011;28:110-25. https://doi.org/10.1007/s12325-010-0101-y
  15. Weisman LE. Respiratory syncytial virus (RSV) prevention and treatment: past, present, and future. Cardiovasc Hematol Agents Med Chem 2009;7:223-33. https://doi.org/10.2174/187152509789105471
  16. Krilov LR. Respiratory syncytial virus disease: update on treatment and prevention. Expert Rev Anti Infect Ther 2011;9:27-32. https://doi.org/10.1586/eri.10.140
  17. Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm 2010;16:46-58.
  18. Meissner HC, Long S. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003;112:1447-52. https://doi.org/10.1542/peds.112.6.1447
  19. Fitzgerald DA. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab. Paediatr Respir Rev 2009;10:143-7. https://doi.org/10.1016/j.prrv.2009.06.002
  20. Smart KA, Lanctt KL, Paes BA. The cost effectiveness of palivizumab: a systematic review of the evidence. J Med Econ 2010;13:453-63. https://doi.org/10.3111/13696998.2010.499749
  21. Prescott WA, Doloresco F, Brown J, Paladino JA. Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review. Pharmacoeconomics 2010;28:279-93. https://doi.org/10.2165/11531860-000000000-00000
  22. Hampp C, Kauf TL, Saidi AS, Winterstein AG. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med 2011;May 5.[Epub ahead of print]
  23. Lacaze-Masmonteil T, Seidenberg J, Mitchell I, Cossey V, Cihar M, Csader M, et al. Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection. Drug Saf 2003;26:283-91. https://doi.org/10.2165/00002018-200326040-00005
  24. Null D, Pollara B, Dennehy PH, Steichen J, Snchez PJ, Givner LB, et al. Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. Pediatr Infect Dis J 2005;24:1021-3. https://doi.org/10.1097/01.inf.0000183938.33484.bd
  25. Adams O, Bonzel L, Kovacevic A, Mayatepek E, Hoehn T, Vogel M. Palivizumab-resistant human respiratory syncytial virus infection in infancy. Clin Infect Dis 2010;51:185-8. https://doi.org/10.1086/653534
  26. DeVincenzo JP, Hall CB, Kimberlin DW, Snchez PJ, Rodriguez WJ, Jantausch BA, et al. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J Infect Dis 2004;190:975-8. https://doi.org/10.1086/423213
  27. Georgescu G, Chemaly RF. Palivizumab: where to from here? Expert Opin Biol Ther 2009;9:139-47. https://doi.org/10.1517/14712590802610692
  28. Hu J, Robinson JL. Treatment of respiratory syncytial virus with palivizumab: a systematic review. World J Pediatr 2010;6:296-300. https://doi.org/10.1007/s12519-010-0230-z
  29. Cingoz O. Motavizumab. MAbs 2009;1:439-42. https://doi.org/10.4161/mabs.1.5.9496
  30. Gill MA, Welliver RC. Motavizumab for the prevention of respiratory syncytial virus infection in infants. Expert Opin Biol Ther 2009;9:1335-45. https://doi.org/10.1517/14712590903287499
  31. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969;89:435-48.
  32. Murphy BR, Walsh EE. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 1988;26:1595-7.
  33. Olson MR, Varga SM. CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J Immunol 2007;179:5415-24. https://doi.org/10.4049/jimmunol.179.8.5415
  34. Adair BM. Nanoparticle vaccines against respiratory viruses. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009;1:405-14. https://doi.org/10.1002/wnan.45
  35. Murata Y. Respiratory syncytial virus vaccine development. Clin Lab Med 2009;29:725-39. https://doi.org/10.1016/j.cll.2009.07.004
  36. Blanco JC, Boukhvalova MS, Shirey KA, Prince GA, Vogel SN. New insights for development of a safe and protective RSV vaccine. Hum Vaccin 2010;6:482-92. https://doi.org/10.4161/hv.6.6.11562

피인용 문헌

  1. Clinical characteristics of respiratory virus infection in children admitted to an intensive care unit vol.1, pp.4, 2011, https://doi.org/10.4168/aard.2013.1.4.370
  2. Prevention and prophylaxis of respiratory syncytial virus in pediatric cardiology: a UK perspective vol.10, pp.2, 2011, https://doi.org/10.2217/fca.14.4